Project Grant R35GM165638
Award Date 8/1/26
Completion Date 3/31/31
Dollars Obligated $386K
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
GRANDVIEW, OH 43212, USA
Similar Awards
- The National Institute of General Medical Sciences awarded the University of Massachusetts Medical School $1,675,000 on May 1, 2026, under the Biomedical Research and Research Training program (CFDA 93.859) to interrogate the roles of truncated and mutated inverted terminal repeat (ITR) sequences in adeno-associated virus (AAV) vectors and their effects on transgene stability through episome formation and host cell genome integration. The project, designated R01GM155648, addresses a critical gap...
- The National Institute of General Medical Sciences awarded The Ohio State University $419,674 on May 1, 2026, under the Biomedical Research and Research Training program (CFDA 93.859) to conduct structural and functional studies of gene regulation by small noncoding RNAs, specifically tiny guide RNAs (tyhRNAs) and their interactions with human Argonaute proteins. The research addresses five key topics: the molecular mechanisms by which AGO2 and AGO3 proteins loaded with cleavage-inducing tyhRNAs...
- The National Institute of Allergy and Infectious Diseases awarded The Ohio State University $433,125 on July 1, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to examine the subcellular proteome in response to influenza infection. The recipient will characterize and optimize AAV vectors for transduction of human precision cut lung slices (PCLS), test the localization efficiency of targeted MICROID2 constructs (a promiscuous biotin-ligase for measuring...
- The National Institute of General Medical Sciences awarded The Ohio State University $383,169 on July 23, 2026, under the Biomedical Research and Research Training program (CFDA 93.859) to develop AI-powered computational models for translational research that benchmark the fidelity of animal models and organoid systems against human references and construct ensemble virtual cells to predict human cellular responses under perturbations. The award funds two integrated research directions....
- Federal Grant Award Summary The Ohio State University received a $374,199 Project Grant from the National Center for Advancing Translational Sciences (NCATS, CFDA 93.350) awarded on July 7, 2025, with completion anticipated by June 30, 2027. The grant supports development of an in situ capsid protein and deoxyribonucleic acid (DNA) imaging platform designed to characterize and quantify therapeutic adeno-associated virus (AAV) titers with enhanced precision and accuracy. The research addresses...
- The National Institute of General Medical Sciences awarded The Ohio State University $403,373 on July 15, 2026, under the Biomedical Research and Research Training program (CFDA 93.859) to conduct research on the molecular mechanisms of circadian gene regulation. The research addresses how a single 24-hour circadian oscillator supports multiphasic gene expression across organisms. The project integrates in vitro biochemical assays with genetic tools in the cyanobacterium Synechococcus...
- The National Institute of General Medical Sciences awarded The Ohio State University $410,893 on March 1, 2026, under the Biomedical Research and Research Training program (CFDA 93.859) to conduct genomics-accelerated discovery and biosynthesis research on phosphonic acid natural products. The project, identified as R35GM161629, runs through December 31, 2030, with performance at Columbus, Ohio. The research program aims to discover microbial natural products of chemotherapeutic value, establish...
- The National Institute of Allergy and Infectious Diseases, within the Department of Health and Human Services, awarded The Ohio State University $354,416 on February 2, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855). The award funds research into novel peroxisome functions in Histoplasma capsulatum pathogenesis. The research will define the peroxisome proteome and metabolome in pathogenic-phase fungal cells to uncover new peroxisomal roles beyond known functions...
- The National Institute of Allergy and Infectious Diseases awarded The Ohio State University $3.1 million on September 1, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to investigate CD8 T cell mechanisms of influenza virus clearance and pathology in cardiac tissue. The research addresses viral myocarditis, detected in up to 40 percent of hospitalized influenza patients and linked to higher risk of heart failure and death. Using a newly developed heart-tropic,...
- The National Institute of Allergy and Infectious Diseases awarded The Ohio State University $670,881 on April 1, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to investigate how Anaplasma phagocytophilum, the causative agent of human granulocytic anaplasmosis, exploits host cell endoplasmic reticulum-Golgi transport machinery to facilitate infection. The research focuses on a bacterial Type IV secretion system effector protein called EGEA (endoplasmic...